Predictive biomarkers for dasatinib treatment in melanoma. - Wikidata - wikimedia - TriplyDB

Predictive biomarkers for dasatinib treatment in melanoma.

Predictive biomarkers for dasatinib treatment in melanoma.

http://www.wikidata.org/entity/Q34781153

about

Tumour progression and metastasis Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells

P2860

Q26766468-D2137901-225D-4DFC-8FE2-8D56A8945ADE Q35987334-7D1AFD13-B9C2-480C-ABF2-21561F19D24F Q36188833-01F706E6-FDF0-4180-8DFD-9D2F80A02C15

P2860

Predictive biomarkers for dasatinib treatment in melanoma.

http://www.wikidata.org/entity/Q34781153

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Predictive biomarkers for dasatinib treatment in melanoma.

@ast

Predictive biomarkers for dasatinib treatment in melanoma.

@en

Predictive biomarkers for dasatinib treatment in melanoma.

@nl

type

label

Predictive biomarkers for dasatinib treatment in melanoma.

@ast

Predictive biomarkers for dasatinib treatment in melanoma.

@en

Predictive biomarkers for dasatinib treatment in melanoma.

@nl

prefLabel

Predictive biomarkers for dasatinib treatment in melanoma.

@ast

Predictive biomarkers for dasatinib treatment in melanoma.

@en

Predictive biomarkers for dasatinib treatment in melanoma.

@nl

P1433

Q34781153-DF9F6542-434E-4075-A8E5-0EAA951165D1

P1476

Q34781153-F67D87BD-095B-4B2A-A048-B85427C45FD4

P2093

Q34781153-038C73A1-0909-45F4-AF80-2CDE4B0ACF3C

Q34781153-1C526B06-24E7-4CD7-9A63-7B71AC92EDD1

Q34781153-2777E1C9-4750-4FE4-9112-219D57EE1538

Q34781153-372DDB57-1A02-495D-97C4-1D0E73B634C8

Q34781153-466A089C-E2F2-42D3-9447-3DD2A456BDC4

Q34781153-A5848061-6D19-4412-A7E2-CCF740243D45

Q34781153-ECFC371E-6064-4C82-918A-7417BB5943FC

P2860

Q34781153-0BDAF284-6FC2-43FC-9F15-B004744E99F8

Q34781153-2445BE40-909E-4CA3-BF38-9D8930EA2AA2

Q34781153-25DF7D6D-9BDF-4C38-8A3E-2D6B74B3EA4E

Q34781153-2F048240-DE6D-415A-B367-A9FA4F6F15A3

Q34781153-30A3F241-0B8F-4860-8D00-88E7141E097C

Q34781153-3C34F847-6041-420A-8DE4-E85C85313F08

Q34781153-4F1E7219-3AC1-446D-B065-57FC7305430E

Q34781153-514890B4-0540-4D35-B055-8C8D7213EB16

Q34781153-53019342-F6F5-479C-BE83-6AAA549A2EE8

Q34781153-56353739-14BF-48B4-9883-AAB4A2BEFCF7

P304

Q34781153-AE33C3B4-02D2-40B9-9290-E7AC3D9C475E

P31

Q34781153-60F16B82-79BC-4602-A42D-4B322E417F59

P356

Q34781153-EDBF5D67-62B7-4428-924C-4323D277821D

P433

Q34781153-CC3E55ED-D454-4ACF-8885-6D0CB36E234A

P478

Q34781153-8012F058-8BEF-4AE8-9FDB-93730B14FEF9

P50

Q34781153-6E14F36D-05BC-4EF9-BDD8-E5AF8167337A

Q34781153-A1F0C7B6-61F3-4743-AA14-B2D2639D3B42

P577

Q34781153-1A7C0737-0453-44FB-A894-1B3BEB68EBFE

P5875

Q34781153-8FD4A569-7992-45D0-A3C0-122AE2B60713

P698

Q34781153-D191E5ED-F358-4B13-9649-2B75E050AD72

P921

Q34781153-F954EB8F-BA09-4210-9EF6-FABC74955352

P932

Q34781153-997E9362-E79E-4B99-9EBF-E49EBA75FEAE

P356

P1433

P1476

Predictive biomarkers for dasatinib treatment in melanoma.

@en

P2093

Anne-Marie Larkin

http://www.w3.org/2001/XMLSchema#string

Dimitrios Tryfonopoulos

http://www.w3.org/2001/XMLSchema#string

John Crown

http://www.w3.org/2001/XMLSchema#string

Martin Clynes

http://www.w3.org/2001/XMLSchema#string

Norma O'Donovan

http://www.w3.org/2001/XMLSchema#string

Susan Kennedy

http://www.w3.org/2001/XMLSchema#string

Thamir Mahgoub

http://www.w3.org/2001/XMLSchema#string

P2860

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Nivolumab plus ipilimumab in advanced melanoma.

Redox-induced Src kinase and caveolin-1 signaling in TGF-β1-initiated SMAD2/3 activation and PAI-1 expression

Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin Activation.

High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.

Elevated c-Src and c-Yes expression in malignant skin cancers

CAV1 inhibits metastatic potential in melanomas through suppression of the integrin/Src/FAK signaling pathway.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

A phase 2 trial of dasatinib in advanced melanoma.

P304

158-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOSCIENCE.20

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Lorraine O'Driscoll

Alex J. Eustace

P577

2014-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270907406

http://www.w3.org/2001/XMLSchema#string

P698

25594008

http://www.w3.org/2001/XMLSchema#string

P921

P932

4278284

http://www.w3.org/2001/XMLSchema#string